Laventair Ellipta

Umeclidinium bromide / Vilanterol, the active ingredient in Laventair Ellipta, is a LAMA/LABA combination presented as a dry powder inhaler for inhalation use. It provides long‑acting bronchodilation for maintenance therapy in patients with chronic obstructive pulmonary disease and asthma.

GNH USA supplies Laventair Ellipta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides reliable logistics for bulk and individual orders. All shipments are accompanied by full regulatory documentation to ensure compliance with import requirements.

Laventair Ellipta, a LAMA/LABA bronchodilator, is indicated for chronic airway diseases requiring long‑term maintenance therapy.

- Chronic obstructive pulmonary disease (COPD): improves lung function, reduces exacerbation frequency, enhances symptom control, and may increase exercise tolerance. - Asthma: provides sustained bronchodilation to aid maintenance treatment, improve daily symptom management, and decrease reliance on rescue inhalers. - Bronchospasm associated with COPD or asthma: helps maintain open airways, prevent airflow limitation, and support overall respiratory stability.

Common and serious adverse reactions have been reported with inhaled LAMA/LABA combinations.

Common Side Effects: - Cough - Throat irritation - Dry mouth - Headache

Serious or Rare Side Effects: - Paradoxical bronchospasm - Tachycardia or arrhythmia - Severe allergic reactions including anaphylaxis - Angioedema

Before prescribing Laventair Ellipta, clinicians should consider several safety measures.

- Assess cardiovascular status: monitor for tachycardia, arrhythmias, or hypertension. - Review patient’s asthma/COPD control: ensure appropriate maintenance regimen before initiating therapy. - Avoid use in individuals with known hypersensitivity to umeclidinium, vilanterol, or excipients. - Use caution in patients with severe renal impairment: adjust monitoring as needed. - Educate on proper inhaler technique: incorrect use may increase local irritation or reduce efficacy. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Laventair Ellipta may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator response and increase risk of bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise systemic exposure to vilanterol. - Monoamine oxidase inhibitors (MAOIs): potential for hypertensive reactions when combined with β2‑agonists.

Moderate Interactions (Monitor Closely): - Other bronchodilators (short‑acting β2‑agonists or anticholinergics): additive effects may increase heart rate or cause tremor. - Diuretics: may exacerbate hypokalemia, especially with β2‑agonist activity. - Anticholinergic drugs: combined anticholinergic load may increase dry mouth or urinary retention.